| 1. |
- Costanza, Robert, et al.
(författare)
-
Developing an Integrated History and future of People on Earth (IHOPE)
- 2012
-
Ingår i: Current Opinion in Environmental Sustainability. - : Elsevier BV. - 1877-3435 .- 1877-3443. ; 4:1, s. 106-114
-
Tidskriftsartikel (refereegranskat)abstract
- The Integrated History and future of People on Earth (IHOPE) initiative is a global network of researchers and research projects with its International Program Office (IPO) now based at the Stockholm Resilience Center (SRC), Uppsala University, Arizona State University, Portland State University, and the Australian National University. Research linked to IHOPE demonstrates that Earth system changes in the past have been strongly associated with changes in the coupled human-environment system. IHOPE supports integrating knowledge and resources from the biophysical and the social sciences and the humanities to address analytical and interpretive issues associated with coupled human-earth system dynamics. This integration of human history and Earth system history is a timely and important task. Until recently, however, there have been few attempts at such integration. IHOPE will create frameworks that can be used to help achieve this integration. The overarching goal is to produce a rich understanding of the relationships between environmental and human processes over the past millennia. HOPE recognizes that one major challenge for reaching this goal is developing 'workable' terminology that can be accepted by scholars of all disciplines. The specific objectives for IHOPE are to identify slow and rapidly moving features of complex social-ecological systems, on local to continental spatial scales, which induce resilience, stress, or collapse in linked systems of humans in nature. These objectives will be reached by exploring innovative ways of conducting interdisciplinary and transdisciplinary science, including theory, case studies, and integrated modeling. Examples of projects underway to implement this initiative are briefly discussed.
|
|
| 2. |
- Ding, Yuan C, et al.
(författare)
-
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers
- 2012
-
Ingår i: Cancer Epidemiology, Biomarkers and Prevention. - : American Association for Cancer Research. - 1055-9965 .- 1538-7755. ; 21:8, s. 1362-1370
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: We previously reported significant associations between genetic variants in insulin receptor substrate 1 (IRS1) and breast cancer risk in women carrying BRCA1 mutations. The objectives of this study were to investigate whether the IRS1 variants modified ovarian cancer risk and were associated with breast cancer risk in a larger cohort of BRCA1 and BRCA2 mutation carriers.METHODS: IRS1 rs1801123, rs1330645, and rs1801278 were genotyped in samples from 36 centers in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Data were analyzed by a retrospective cohort approach modeling the associations with breast and ovarian cancer risks simultaneously. Analyses were stratified by BRCA1 and BRCA2 status and mutation class in BRCA1 carriers.RESULTS: Rs1801278 (Gly972Arg) was associated with ovarian cancer risk for both BRCA1 (HR, 1.43; 95% confidence interval (CI), 1.06-1.92; P = 0.019) and BRCA2 mutation carriers (HR, 2.21; 95% CI, 1.39-3.52, P = 0.0008). For BRCA1 mutation carriers, the breast cancer risk was higher in carriers with class II mutations than class I mutations (class II HR, 1.86; 95% CI, 1.28-2.70; class I HR, 0.86; 95%CI, 0.69-1.09; P(difference), 0.0006). Rs13306465 was associated with ovarian cancer risk in BRCA1 class II mutation carriers (HR, 2.42; P = 0.03).CONCLUSION: The IRS1 Gly972Arg single-nucleotide polymorphism, which affects insulin-like growth factor and insulin signaling, modifies ovarian cancer risk in BRCA1 and BRCA2 mutation carriers and breast cancer risk in BRCA1 class II mutation carriers.Impact: These findings may prove useful for risk prediction for breast and ovarian cancers in BRCA1 and BRCA2 mutation carriers.
|
|
